Having already secured initial FDA approval for its flagship product in vascular trauma indications, Humacyte is actively pursuing expanded regulatory clearances for additional clinical applications, such as hemodialysis access. While the company engages in productive communications with regulatory bodies and submits comprehensive Phase 3 clinical trial datasets to support supplemental applications, ultimate approval timelines remain subject to formal FDA review outcomes.